West Pharmaceutical Services (WST) Stock
Key components supplier for injectable drug delivery. Here's the price, business snapshot, and what's worth knowing about West Pharmaceutical Services in September 2026.
West Pharmaceutical Services Inc (WST) supplies components and delivery systems for injectable drugs and vaccines, including stoppers, seals, syringe components and containment technologies. Its customers are pharmaceutical and biotechnology companies that rely on high-quality, regulatory-compliant components for sterile drug packaging and drug delivery. West benefits from long-term trends such as growth in biologic medicines, injectable therapeutics and outsourcing of containment and delivery manufacturing, supporting steady demand for precision components. Investors should note the company operates in a manufacturing- and technology-intensive niche where quality, regulatory approval and supply-chain resilience are key competitive advantages. Financially, West is a mid-cap company (market cap approx. $20.1bn) with a history of generating operating cash flow, though revenues can be influenced by customers' development cycles and contract timing. Key risks include regulatory scrutiny, competition, raw-material and manufacturing disruptions, and customer concentration. This summary is educational only and not personalised investment advice; perform your own due diligence.
Why It’s Moving
WST Shares Climb on Momentum from Prior Earnings Beat and GLP-1 Demand Surge
- Q3 EPS of $1.96 crushed estimates by $0.29, with revenue up 7.7% YoY to $804.6M, underscoring resilient organic growth and margin resilience.
- Management lifted FY2025 EPS outlook to $7.06-$7.11 and revenue toward $3.1B, signaling confidence in sustained demand for specialized drug delivery systems.
- KeyCorp analysts upgraded their target and rating, spotlighting GLP-1 tailwinds and high-volume packaging expansions as pivotal upside drivers.
WST Shares Climb on Momentum from Prior Earnings Beat and GLP-1 Demand Surge
- Q3 EPS of $1.96 crushed estimates by $0.29, with revenue up 7.7% YoY to $804.6M, underscoring resilient organic growth and margin resilience.
- Management lifted FY2025 EPS outlook to $7.06-$7.11 and revenue toward $3.1B, signaling confidence in sustained demand for specialized drug delivery systems.
- KeyCorp analysts upgraded their target and rating, spotlighting GLP-1 tailwinds and high-volume packaging expansions as pivotal upside drivers.
Sixth Month Growth Performance
When is the next earnings date for WEST PHARMACEUTICAL SERVICES INC (WST)?
West Pharmaceutical Services (WST) has its next earnings call scheduled for April 23, 2026, covering results for Q1 2026. This follows the pattern of late April releases observed in prior quarters, with the most recent report on February 12, 2026, addressing Q4 2025. Investors should monitor for official confirmation, as estimates align across multiple historical data points.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying West Pharmaceutical Services' stock with a target price of $397.73, indicating growth potential.
Financial Health
West Pharmaceutical Services is performing well with healthy revenue, profits, and cash flow.
Dividend
West Pharmaceutical's dividend yield of 0.24% is quite low, indicating limited dividend payments. If you invested $1000 you would be paid $2.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Demand from biologics
Biologic and injectable drug growth supports long-term demand for precision components, though revenue timing can vary with customers' development cycles.
Quality and execution
Manufacturing excellence and regulatory compliance are competitive advantages, but execution and supply‑chain disruptions can materially affect results.
Exposure to pharma
West offers indirect exposure to global pharmaceutical and biotech activity, balanced by risks such as customer concentration and regulatory scrutiny.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
